One of the ostensible topics of discussion was the benefits and potential of blood-based cancer screening tests. These tests offer various opportunities for players across the diagnostic and clinical value chain to create significant clinical and commercial value. But they also require a rethinking on the part of everyone involved: patients, doctors, authorities, insurers, etc.

As co-founder of one of the first Swiss liquid biopsy startups for the early detection of cancer from patient blood, Dr. Arne-C. Faisst has been able to make a valuable contribution to the discussion on personalized patient care with his profound expertise.